Sansei Guojian: Sansei Guojian: Report for the first quarter of 2025

SZSIApr 22 12:00 ET · Announcements

Sansei Guojian: Report for the first quarter of 2025

SZSIApr 22 12:00 ET · Announcements

Sunshine Guojian Pharmaceutical: Q1 revenue grew by 16.6%, with several positive developments in the R&D pipeline.

Sunshine Guojian Pharmaceutical's Q1 revenue grew by 16.6%, with multiple positive developments in the R&D pipeline. Summary of key points: Financial performance: Q1 revenue in 2025 was 0.311 billion...

wallstreetcnApr 22 06:43 ET

Sunshine Guojian Pharmaceutical (688336.SH): In the first quarter, the Net income was 0.103 billion yuan, an increase of 12.99% year-on-year.

Glory Times reported on April 22 that Sunshine Guojian Pharmaceutical (688336.SH) announced its first quarterly report for 2025, achieving revenue of 0.311 billion yuan during the reporting period, a year-on-year increase of 16.57%; net income attributable to shareholders of the listed company was 0.103 billion yuan, a year-on-year growth of 12.99%; the basic EPS was 0.17 yuan.

Gelonghui FinanceApr 22 06:09 ET

Estimating The Intrinsic Value Of Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (SHSE:688336)

Simply Wall StApr 9 02:36 ET

Brokerage morning meeting highlights: The USA has increased tariffs on China, but the impact on these industries in the A-shares may be limited.

In today's brokerage morning meeting, GF SEC believes that the USA's tariffs on China have a limited impact on the A-share Computer Industry; China Securities Co.,Ltd. suggested being Bullish on the Innovative Drugs industry that is currently not affected by tariffs; Galaxy Securities stated that Deep Sea Technology has entered a new stage in Global Strategy, focusing on opportunities in core equipment.

cls.cnApr 6 20:17 ET